Literature DB >> 25732498

Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.

Christine Buttorff1, Martin S Andersen2, Kevin R Riggs3, G Caleb Alexander4.   

Abstract

Just under seven million Americans acquired private insurance through the new health insurance exchanges, or Marketplaces, in 2014. The exchange plans are required to cover essential health benefits, including prescription drugs. However, the generosity of prescription drug coverage in the plans has not been well described. Our primary objective was to examine the variability in drug coverage in the exchanges across plan types (health maintenance organization or preferred provider organization) and metal tiers (bronze, silver, gold, and platinum). Our secondary objective was to compare the exchange coverage to employer-sponsored coverage. Analyzing prescription drug benefit design data for the federally facilitated exchanges, we found wide variation in enrollees' out-of-pocket costs for generic, preferred brand-name, nonpreferred brand-name, and specialty drugs, not only across metal tiers but also within those tiers across plan types. Compared to employer-sponsored plans, exchange plans generally had lower premiums but provided less generous drug coverage. However, for low-income enrollees who are eligible for cost-sharing subsidies, the exchange plans may be more comparable to employer-based coverage. Policies and programs to assist consumers in matching their prescription drug needs with a plan's benefit design may improve the financial protection for the newly insured. Project HOPE—The People-to-People Health Foundation, Inc.

Keywords:  Health Reform; cost sharing; health insurance; health insurance exchanges; prescription drug benefits

Mesh:

Substances:

Year:  2015        PMID: 25732498     DOI: 10.1377/hlthaff.2014.0615

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  6 in total

1.  States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Jennifer R Havens; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

2.  Simulating Variation in Families' Spending across Marketplace Plans.

Authors:  Yuting Zhang; Seo Hyon Baik; Samuel H Zuvekas
Journal:  Health Serv Res       Date:  2018-02-14       Impact factor: 3.402

3.  Buprenorphine physician supply: Relationship with state-level prescription opioid mortality.

Authors:  Hannah K Knudsen; Jennifer R Havens; Michelle R Lofwall; Jamie L Studts; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2017-04-01       Impact factor: 4.492

4.  Perceived Impacts of the Affordable Care Act: Perspectives of Buprenorphine Prescribers.

Authors:  Hannah K Knudsen; Jamie L Studts
Journal:  J Psychoactive Drugs       Date:  2017-03-15

5.  The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2015-12-01

6.  Risk-Adjustment Simulation: Plans May Have Incentives To Distort Mental Health And Substance Use Coverage.

Authors:  Ellen Montz; Tim Layton; Alisa B Busch; Randall P Ellis; Sherri Rose; Thomas G McGuire
Journal:  Health Aff (Millwood)       Date:  2016-06-01       Impact factor: 6.301

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.